

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH ASTHMA

1. Abramson MJ, Puy RM, Weiner JM: **Injection allergen immunotherapy for asthma.** *The Cochrane database of systematic reviews* 2010(8):CD001186.
2. Alangari AA: **Corticosteroids in the treatment of acute asthma.** *Ann Thorac Med* 2014, **9**(4):187-192.
3. Anderson DE, Kew KM, Boyter AC: **Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma.** *The Cochrane database of systematic reviews* 2015(8):CD011397.
4. ANI Pharmaceuticals Inc: **Terbutaline Sulfate.** In: *US Product Monograph.* Baudette, MN; 2018.
5. AstraZeneca Canada Inc: **Pulmicort Turbuhaler (budesonide).** In: *CA Product Monograph.* Mississauga, ON; 2017.
6. AstraZeneca Canada Inc: **Alvesco (ciclesonide).** In: *CA Product Monograph.* Mississauga, ON; 2017.
7. AstraZeneca Canada Inc: **Oxeze Turbuhaler (formoterol fumarate dihydrate).** In: *CA Product Monograph.* Mississauga, ON; 2018.
8. AstraZeneca Canada Inc: **Bricanyl Turbuhaler (terbutaline sulfate).** In: *CA Product Monograph.* Mississauga, ON; 2018.
9. AstraZeneca Pharmaceuticals LP: **Pulmicort Respules (budesonide)** In: *US Product Monograph.* Wilmington, DE; 2018.
10. AstraZeneca Pharmaceuticals LP: **Pulmicort Flexhaler (budesonide).** In: *US Product Monograph.* Wilmington DE; 2018.
11. Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S: **Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol.** *The Journal of allergy and clinical immunology* 2009, **124**(6):1188-1194.e1183.
12. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM: **Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.** *The Journal of allergy and clinical immunology* 2011, **128**(2):315-322.
13. Becker AB, Simons FE: **Formoterol, a new long-acting selective beta 2-adrenergic receptor agonist: double-blind comparison with salbutamol and placebo in children with asthma.** *The Journal of allergy and clinical immunology* 1989, **84**(6 Pt 1):891-895.
14. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, Investigators S: **Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.** *The New England journal of medicine* 2014, **371**(13):1189-1197.

15. Bleecker ER, Yancey SW, Baitinger LA, Edwards LD, Klotsman M, Anderson WH, Dorinsky PM: **Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.** *The Journal of allergy and clinical immunology* 2006, **118**(4):809-816.
16. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M: **Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.** *Lancet (London, England)* 2007, **370**(9605):2118-2125.
17. Bleecker ER, Meyers DA, Bailey WC, Sims AM, Bujac SR, Goldman M, Martin UJ: **ADRB2 polymorphisms and budesonide/formoterol responses in COPD.** *Chest* 2012, **142**(2):320-328.
18. Boehringer Ingelheim (Canada) Ltd: **Spiriva (tiotropium).** In: *CA Product Monograph.* Burlington, ON; 2017.
19. Boehringer Ingelheim (Canada) Ltd: **Spiriva Respimat (tiotropium).** In: *CA Product Monograph.* Burlington, ON; 2019.
20. Boehringer Ingelheim Pharmaceuticals Inc: **Spiriva Handihaler (tiotropium).** In: *US Product Monograph.* Ridgefield, CT; 2018.
21. Boehringer Ingelheim Pharmaceuticals Inc: **Spiriva Respimat (tiotropium).** In: *US Product Monograph.* Ridgefield, CT 2019.
22. Bonini M, Permaul P, Kulkarni T, Kazani S, Segal A, Sorkness CA, Wechsler ME, Israel E: **Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.** *American journal of respiratory and critical care medicine* 2013, **188**(12):1407-1412.
23. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD: **The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.** *Allergy* 2005, **60**(3):302-308.
24. British Columbia Guidelines and Protocols Advisory Committee: **Asthma in Adults - Recognition, Diagnosis and Management.** In. Edited by Association BCM. Victoria, BC: Guidelines and Protocols Advisory Committee; 2015.
25. British Columbia Guidelines and Protocols Advisory Committee: **Asthma in children - diagnosis and management.** In. Edited by Association BCM,
edn. Victoria, BC: Guidelines and Protocols Advisory Committee; 2015.
26. British Thoracic Society SIGN: **British guideline for the management of asthma; a national clinical guideline (SIGN 158).** In.; 2019.
27. Calamita Z, Saconato H, Pela AB, Atallah AN: **Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method.** *Allergy* 2006, **61**(10):1162-1172.

28. Cao Y, Wang J, Bunjhoo H, Xie M, Xu Y, Fang H: **Comparison of leukotriene receptor antagonists in addition to inhaled corticosteroid and inhaled corticosteroid alone in the treatment of adolescents and adults with bronchial asthma: a meta-analysis.** *Asian Pacific journal of allergy and immunology* 2012, **30**(2):130-138.
29. Chauhan BF, Ducharme FM: **Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.** *The Cochrane database of systematic reviews* 2014(1):CD003137.
30. Compalati E, Passalacqua G, Bonini M, Canonica GW: **The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis.** *Allergy* 2009, **64**(11):1570-1579.
31. Covis Pharma: **Alvesco (ciclesonide).** In: *US Product Monograph.* Zug, Switzerland; 2018.
32. Cross KP, Paul RI, Goldman RD: **Single-dose dexamethasone for mild-to-moderate asthma exacerbations: effective, easy, and acceptable.** *Canadian family physician Medecin de famille canadien* 2011, **57**(10):1134-1136.
33. Dahl R: **Ciclesonide for the treatment of asthma.** *Ther Clin Risk Manag* 2006, **2**(1):25-38.
34. de Blic J, Ogorodova L, Klink R, Sidorenko I, Valiulis A, Hofman J, Bennedbaek O, Anderton S, Attali V, Desfougeres JL *et al*: **Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children.** *Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology* 2009, **20**(8):763-771.
35. Dijkstra A, Koppelman GH, Vonk JM, Bruinenberg M, Schouten JP, Postma DS: **Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms.** *The Journal of allergy and clinical immunology* 2008, **121**(6):1510-1513.
36. Ducharme FM: **Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence.** *BMJ* 2003, **326**(7390):621.
37. Ducharme FM, Dell SD, Radhakrishnan D, Grad RM, Watson WT, Yang CL, Zelman M: **Diagnosis and management of asthma in preschoolers: A Canadian Thoracic Society and Canadian Paediatric Society position paper.** *Canadian respiratory journal* 2015, **22**(3):135-143.
38. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: **Long-term clinical efficacy of grass-pollen immunotherapy.** *The New England journal of medicine* 1999, **341**(7):468-475.
39. Evans DJ, Kew KM, Anderson DE, Boyter AC: **Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma.** *The Cochrane database of systematic reviews* 2015(7):CD011437.
40. Falk NP, Hughes SW, Rodgers BC: **Medications for Chronic Asthma.** *American family physician* 2016, **94**(6):454-462.

41. Finkelstein Y, Bournissen FG, Hutson JR, Shannon M: **Polymorphism of the ADRB2 gene and response to inhaled beta- agonists in children with asthma: a meta-analysis.** *J Asthma* 2009, **46**(9):900-905.
42. Gappa M, Zachgo W, von Berg A, Kamin W, Stern-Strater C, Steinkamp G: **Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED).** *Pediatric pulmonology* 2009, **44**(11):1132-1142.
43. Giubergia V, Gravina L, Castanos C, Chertkoff L: **Influence of beta(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.** *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology* 2013, **110**(3):156-160.
44. GlaxoSmithKline Inc: **Serevent Diskhaler/Diskus (salmeterol).** In: *CA Product Monograph.* Mississauga, ON; 2014.
45. GlaxoSmithKline Inc: **Ventolin Diskus (salbutamol sulfate DPI)** In: *CA Product Monograph.* Mississauga, ON; 2017.
46. GlaxoSmithKline Inc: **Ventolin Nebules and Respirator (salbutamol sulfate solution).** In: *CA Product Monograph.* Mississauga, ON; 2017.
47. GlaxoSmithKline Inc: **Ventolin HFA (salbutamol sulfate).** In: *CA Product Monograph.* Mississauga, ON; 2017.
48. GlaxoSmithKline Inc: **Flovent HFA and Diskus (fluticasone propionate).** In: *CA Product Monograph.* Mississauga, ON; 2018.
49. GlaxoSmithKline LLC: **Serevent Diskus (salmeterol).** In: *US Product Monograph.* Research Triangle Park, NC; 2016.
50. GlaxoSmithKline LLC: **Ventolin HFA (albuterol sulfate).** In: *US Product Monograph.* Research Triangle Park, NC; 2018.
51. GlaxoSmithKline LLC: **Flovent HFA (fluticasone propionate).** In: *US Product Monograph.* Research Triangle Park, NC; 2019.
52. GlaxoSmithKline LLC: **Serevent Diskus (salmeterol).** In: *US Product Monograph.* Research Triangle Park, NC; 2019.
53. Global Initiative for Asthma: **Global strategy for asthma management and prevention.** In.; 2017.
54. **Global strategy for asthma management and prevention** [www.ginasthma.org]
55. Hizawa N, Makita H, Nasuhara Y, Betsuyaku T, Itoh Y, Nagai K, Hasegawa M, Nishimura M: **Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD.** *Chest* 2007, **132**(5):1485-1492.
56. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J *et al*: **Efficacy and safety of a recombinant anti-immunoglobulin E antibody**

- (omalizumab) in severe allergic asthma.** *Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology* 2004, **34**(4):632-638.
57. Impax Generics: **Levalbuterol**. In: *US Product Monograph*. Heyward, CA; 2017.
 58. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J *et al*: **Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.** *Lancet (London, England)* 2004, **364**(9444):1505-1512.
 59. James DR, Lyttle MD: **British guideline on the management of asthma: SIGN Clinical Guideline 141, 2014.** *Arch Dis Child Educ Pract Ed* 2016, **101**(6):319-322.
 60. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, Schneider A: **Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review.** *Thorax* 2008, **63**(5):453-462.
 61. Kew KM, Evans DJ, Allison DE, Boyter AC: **Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma.** *The Cochrane database of systematic reviews* 2015(6):CD011438.
 62. Kew KM, Dahri K: **Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.** *The Cochrane database of systematic reviews* 2016(1):CD011721.
 63. Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, Lee JH, Kim EK, Lee JH, Lee SM *et al*: **Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease.** *Lung* 2008, **186**(6):381-386.
 64. Kim SH, Ye YM, Hur GY, Lee HY, Jee YK, Lee SH, Holloway JW, Park HS: **Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment.** *Yonsei medical journal* 2009, **50**(2):182-188.
 65. Kips JC, Pauwels RA: **Long-acting inhaled beta(2)-agonist therapy in asthma.** *American journal of respiratory and critical care medicine* 2001, **164**(6):923-932.
 66. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF: **Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.** *The Journal of allergy and clinical immunology* 2009, **124**(6):1210-1216.
 67. Lemanske RF, Jr., Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, Strunk RC, Szeffler SJ, Zeiger RS, Bacharier LB *et al*: **Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.** *The New England journal of medicine* 2010, **362**(11):975-985.
 68. Lipworth BJ, Basu K, Donald HP, Tavendale R, Macgregor DF, Ogston SA, Palmer CN, Mukhopadhyay S: **Tailored second-line therapy in asthmatic children with the Arg(16) genotype.** *Clinical science (London, England : 1979)* 2013, **124**(8):521-528.

69. Loughheed MD, Lemiere C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, Liciskai C, Rowe BH, Bowie D, Becker A *et al*: **Canadian Thoracic Society Asthma Management Continuum--2010 Consensus Summary for children six years of age and over, and adults.** *Canadian respiratory journal* 2010, **17**(1):15-24.
70. Loughheed MD, Lemiere C, Ducharme FM, Liciskai C, Dell SD, Rowe BH, Fitzgerald M, Leigh R, Watson W, Boulet LP: **Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults.** *Canadian respiratory journal* 2012, **19**(2):127-164.
71. Manning P, Gibson PG, Lasserson TJ: **Ciclesonide versus other inhaled steroids for chronic asthma in children and adults.** *The Cochrane database of systematic reviews* 2008(2):CD007031.
72. McGeachie MJ, Wu AC, Chang HH, Lima JJ, Peters SP, Tantisira KG: **Predicting inhaled corticosteroid response in asthma with two associated SNPs.** *The pharmacogenomics journal* 2013, **13**(4):306-311.
73. Merck Canada Inc: **Asmanex Twisthaler (mometasone furoate DPI).** In: *CA Product Monograph.* Kirkland, QC; 2018.
74. Merck Canada Inc: **Zenhale (mometasone furoate / formoterol fumarate dihydrate).** In: *CA Product Monograph.* Kirkland, QC; 2018.
75. Merck Canada Inc: **Singulair (montelukast)** In: *CA Product Monograph.* Kirkland, QC; 2019.
76. Merck Sharp & Dohme Corp: **Asmanex HFA (mometasone furoate).** In: *US Product Monograph.* Whitehouse Station, NJ; 2018.
77. Merck Sharp & Dohme Corp: **Dulera (mometasone furoate / formoterol fumarate dihydrate).** In: *US Product Monograph.* Whitehouse Station, NJ; 2019.
78. Merck Sharp & Dohme Corp: **Singulair (montelukast)** In: *US Product Monograph.* Whitehouse Station, NJ; 2019.
79. Morice AH, Peterson S, Beckman O, Kukova Z: **Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study.** *Pulmonary pharmacology & therapeutics* 2008, **21**(1):152-159.
80. Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, Malcus I, Ljorring C, Canonica GW: **Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.** *The Journal of allergy and clinical immunology* 2014, **134**(3):568-575 e567.
81. Mougey EB, Chen C, Tantisira KG, Blake KV, Peters SP, Wise RA, Weiss ST, Lima JJ: **Pharmacogenetics of asthma controller treatment.** *The pharmacogenomics journal* 2013, **13**(3):242-250.

82. National Asthma Council Australia: **Acute asthma**. In: *Australian Asthma Handbook*. vol. 1.2. Australia, Melbourne: National Asthma Council Australia; 2016.
83. National Institute for Health and Care Excellence: **Asthma: diagnosis, monitoring and chronic asthma management [NICE Guideline NG80]**. In.; 2017.
84. National Institute for Health and Care Excellence: **Chronic asthma: management [NICE Guideline NG80]**. In.; 2017.
85. Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A: **Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses**. *The Journal of allergy and clinical immunology* 2009, **124**(1):157-161 e151-132.
86. Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C: **Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation**. *Health technology assessment (Winchester, England)* 2013, **17**(52):1-342.
87. Normansell R, Walker S, Milan SJ, Walters EH, Nair P: **Omalizumab for asthma in adults and children**. *The Cochrane database of systematic reviews* 2014(1):CD003559.
88. Normansell R, Kew KM, Mansour G: **Different oral corticosteroid regimens for acute asthma**. *The Cochrane database of systematic reviews* 2016(5):CD011801.
89. Novartis Pharmaceuticals Canada Inc: **Foradil (formoterol)**. In: *CA Product Monograph*. Dorval, QC; 2013.
90. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S: **Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol**. *Thorax* 2006, **61**(11):940-944.
91. Pearlman D, Qaqundah P, Matz J, Yancey SW, Stempel DA, Ortega HG: **Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma**. *Pediatric pulmonology* 2009, **44**(5):429-435.
92. Physicians Total Care Inc: **Foradil (formoterol fumarate)**. In: *US Product Monograph*. Whitehouse Station, NJ; 2012.
93. Powell C, Milan SJ, Dwan K, Bax L, Walters N: **Mepolizumab versus placebo for asthma**. *The Cochrane database of systematic reviews* 2015(7):CD010834.
94. Rabe KF, Fabbri LM, Israel E, Kogler H, Riemann K, Schmidt H, Glaab T, Vogelmeier CF: **Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial**. *The Lancet Respiratory medicine* 2014, **2**(1):44-53.
95. Rebordosa C, Kogevinas M, Guerra S, Castro-Giner F, Jarvis D, Cazzoletti L, Pin I, Siroux V, Wjst M, Anto JM *et al*: **ADRB2 Gly16Arg polymorphism, asthma control and lung function decline**. *The European respiratory journal* 2011, **38**(5):1029-1035.

96. Rodrigo GJ, Neffen H, Castro-Rodriguez JA: **Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.** *Chest* 2011, **139**(1):28-35.
97. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW: **Corticosteroids for preventing relapse following acute exacerbations of asthma.** *The Cochrane database of systematic reviews* 2007(3):CD000195.
98. Royal College of Physicians: **Why asthma still kills: the National Review of Asthma Deaths (NRAD) confidential enquiry report.** In. London, UK: RCP; 2014.
99. Shaikh WA: **Immunotherapy vs inhaled budesonide in bronchial asthma: an open, parallel, comparative trial.** *Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology* 1997, **27**(11):1279-1284.
100. Shefrin AE, Goldman RD: **Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients.** *Canadian family physician Medecin de famille canadien* 2009, **55**(7):704-706.
101. Slankard M, Michelis MA, Mansukhani M, McGoey B, Paige A, Andrews H, Lederer D, Canfield S, DiMango E: **Impact of the Arg 16 allele of the B2AR gene on the effect of withdrawal of LABA in patients with moderate to severe asthma.** *J Asthma* 2016, **53**(8):783-789.
102. Soleimani F, Fahimi F, Adimi Naghan P, Nadji SA, Morowati S, Naderi N, Masjedi MR: **The effect of polymorphisms of beta2 adrenoceptors on response to long-acting beta2 agonists in Iranian asthmatic patients.** *Iran J Allergy Asthma Immunol* 2013, **12**(4):383-390.
103. Sunovion Pharmaceuticals Inc: **Xopenex HFA (levalbuterol tartrate).** In: *US Product Monograph.* Marlborough, MA; 2017.
104. Sunovion Pharmaceuticals Inc: **Brovana (arformoterol tartrate).** In: *US Product Monograph.* Marlborough, MA; 2018.
105. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, Liggett SB, Gelfand EW, Rosenwasser LJ, Richter B *et al*: **Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids.** *Human molecular genetics* 2004, **13**(13):1353-1359.
106. Teva Canada Limited: **Budesonide.** In: *CA Product Monograph.* Toronto, ON; 2017.
107. Teva Respiratory LLC: **Proair Respiclick (albuterol sulphate).** In: *US Product Monograph.* Horsham, PA; 2018.
108. Teva Respiratory LLC: **QVAR Redihaler (beclomethasone dipropionate hfa).** In: *US Product Monograph.* Frazer, PA; 2018.
109. Tsartsali L, Papadopoulos M, Lagona E, Papadimitriou A, Kanaka-Gantenbein C, Louizou E, Kastania A, Priftis KN, Chrousos G: **Association of hypothalamic-pituitary-adrenal axis-related polymorphisms with stress in asthmatic children on inhaled corticosteroids.** *Neuroimmunomodulation* 2012, **19**(2):88-95.

110. Turner S, Francis B, Vijverberg S, Pino-Yanes M, Maitland-van der Zee AH, Basu K, Bignell L, Mukhopadhyay S, Tavendale R, Palmer C *et al*: **Childhood asthma exacerbations and the Arg16 beta2-receptor polymorphism: A meta-analysis stratified by treatment.** *The Journal of allergy and clinical immunology* 2016, **138**(1):107-113 e105.
111. Valeant Canada LP: **QVAR (beclomethasone dipropionate)** In: *CA Product Monograph*. Laval, QC; 2013.
112. Virchow JC, Backer V, Kuna P, Prieto L, Nolte H, Villesen HH, Ljorring C, Riis B, de Blay F: **Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial.** *Jama* 2016, **315**(16):1715-1725.
113. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF, Jr., Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ *et al*: **beta-Adrenergic receptor polymorphisms and response to salmeterol.** *American journal of respiratory and critical care medicine* 2006, **173**(5):519-526.
114. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L *et al*: **Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.** *Lancet (London, England)* 2009, **374**(9703):1754-1764.
115. Wechsler ME, Yawn BP, Fuhlbrigge AL, Pace WD, Pencina MJ, Doros G, Kazani S, Raby BA, Lanzillotti J, Madison S *et al*: **Anticholinergic vs Long-Acting beta-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial.** *Jama* 2015, **314**(16):1720-1730.
116. Welsh EJ, Cates CJ: **Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma.** *The Cochrane database of systematic reviews* 2010(9):Cd008418.
117. Yancey SW, Klotsman M, Ortega HG, Edwards LD, Anderson WH: **Acute and chronic lung function responses to salmeterol and salmeterol plus fluticasone propionate in relation to Arg16Gly beta(2)-adrenergic polymorphisms.** *Current medical research and opinion* 2009, **25**(4):1011-1018.
118. Yelensky R, Li Y, Lewitzky S, Leroy E, Hurwitz C, Rodman D, Trifilieff A, Paulding CA: **A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients.** *The pharmacogenomics journal* 2012, **12**(6):484-488.
119. Zuurhout MJ, Vijverberg SJ, Raaijmakers JA, Koenderman L, Postma DS, Koppelman GH, Maitland-van der Zee AH: **Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort.** *Pharmacogenomics* 2013, **14**(16):1965-1971.